Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection
The capacity of cytomegalovirus (CMV) to elicit long-lasting strong T cell responses, and the ability to engineer the genome of this DNA virus positions CMV-based vaccine vectors highly suitable as a cancer vaccine platform. Defined immune thresholds for tumor protection and the factors affecting such thresholds have not well been investigated in cancer immunotherapy. We here determined using CMV as a vaccine platform whether critical thresholds of vaccine-specific T cell responses can be established that relate to tumor protection, and which factors control such thresholds.
We generated CMV-based vaccine vectors expressing the E7 epitope and tested these in preclinical models of HPV16-induced cancer. Vaccination was applied via different doses and routes (intraperitoneal (IP), subcutaneous (SC) and intranasal (IN)). The magnitude, kinetics and phenotype of the circulating tumor-specific CD8+ T cell response were determined. Mice were subsequently challenged with tumor cells, and the tumor protection was monitored.
Immunization with CMV-based vaccines via the IP or SC route eliciting vaccine-induced CD8+ T cell responses of > 0.3% of the total circulating CD8 T cell population fully protects mice against lethal tumor challenge. However, low dose inoculations via the IP or SC route or IN vaccination elicited vaccine-induced CD8+ T cell responses that did not reach protective thresholds for tumor protection. In addition, whereas weak pre-existing immunity did not alter the protective thresholds of the vaccine-specific T cell response following subsequent immunization with CMV-based vaccine vectors, strong pre-existing immunity inhibited the development of vaccine-induced T cells and their control on tumor progression.
This study highlight the effectiveness of CMV-based vaccine vectors, and shows that demarcated thresholds of vaccine-specific T cells could be defined that correlate to tumor protection. Together, these results may hold importance for cancer vaccine development to achieve high efficacy in vaccine recipients.
KeywordsT cells Cancer CMV-based vaccine vector Pre-existing immunity
Adoptive cell therapy
Cluster of differentiation
Dulbecco’s Modified Eagle’s medium
Fetal bovine serum
Fetal calf serum
Human papilloma virus
Iscove’s Modified Dulbecco’s Media
Individually ventilated cages
Penicillin, streptomycin, glutamine
The role of the immune system in cancer eradication has been firmly established. Immunotherapy of cancer has set itself as a mainstream therapy among the conventional therapies comprising chemotherapy, radiotherapy and surgery. Adoptive cell therapy (ACT) with tumor-specific T cells and immunotherapeutic approaches in which the inhibitory pathways are blocked or the costimulatory pathways are triggered to invigorate tumor-specific T cells have shown efficacy in a significant number of patients [1, 2]. Vaccination is another promising form of cancer immunotherapy that has been extensively explored, yet few therapeutic vaccines have shown clinical benefit. The latter has been attributed to the lack of inducing substantial long-lasting functional T cell responses that are able to overcome the immunosuppressive environment .
Immune thresholds are instrumental to determine vaccine efficacy and effectiveness against pathogens . In cancer immunotherapy, however, tumor protection thresholds and the factors affecting such thresholds have not well been investigated although as such they are instrumental for both practical reasons and mechanistic insights. To elicit and maintain high immune responses, cytomegalovirus (CMV) is considered as a promising vaccine vector. CMV is unique among viruses as chronic infection by this common betaherpesvirus is characterized by high frequencies of virus-specific T cells and antibodies that do not decline after primary infection but remain high or even increase over time in a process termed memory inflation [5, 6, 7, 8]. Inflationary T cells are mostly effector-memory (EM)-like in phenotype, remain polyfunctional for life, and are found in both lymphoid organs and tissues . Despite the induction of host immune responses, CMVs are still able to re-infect [10, 11, 12]. Based on these properties, together with the ability to engineer the genome of CMV to attenuate the pathogenicity and to express foreign antigens , CMV-based vaccines are currently being explored. In mice and non-human primates, CMV-based vaccines have demonstrated significant protection against pathogens including simian immunodeficiency virus (SIV), mycobacterium tuberculosis and Ebola virus [14, 15, 16, 17, 18]. Moreover, CMV-based vaccines comprising tumor antigens, including melanoma antigens gp100 and TRP2 [19, 20, 21, 22], human prostate-specific antigen (PSA) , or model antigens like ovalbumin [22, 24], have shown anti-tumor efficacy in prophylactic and therapeutic mouse models.
Here we studied whether thresholds of vaccine-elicited T cell responses could be determined that relate to the efficacy of such vaccines to protect against tumor progression, and which factors influence these thresholds. Specifically, we investigated the vaccine thresholds of CMV-based vaccine vectors and the impact of inoculum dosages and routes of infection to achieve tumor protection. Given the high world-wide CMV prevalence, and the fact that pre-existing immunity varies, as evidenced by large variations in the magnitude of CMV-specific T cell responses in the population, ranging from barely detectable to 40% of the memory compartment, we also addressed the impact of pre-existing immunity on the protective thresholds . Defining protection thresholds could be highly relevant in determining correlates of protection, considered as a crucial element in vaccine development as it provides the level of vaccine efficacy in vaccine recipients.
We found that CMV-based vaccines eliciting clearly discernible CD8+ T cell responses in the blood (> 0.3% of the total CD8 T cell population) fully protected mice against lethal tumor challenge while relatively low responses do not provide protection. Previous exposure to CMV resulting in a weak immune response did not impact vaccine efficacy, however, strong pre-existing immunity hampered the induction of vaccine-induced T cells consequently resulting in loss of tumor protection. The results highlight the premise of CMV-based vaccines, and put forward the potential of such vaccines in halting tumor development based on correlates of protection that are established on careful determination of vaccine-induced immune responses.
C57BL/6 mice were obtained from Charles River Laboratories (L’Arbresle, France) or Jackson Laboratory (Sacramento, CA, USA). At the start of the experiments, mice were 6 to 8 weeks old. Mice were housed in individually ventilated cages (IVC) under specific pathogen-free (SPF) conditions in the animal facility of Leiden University Medical Centre (LUMC, The Netherlands) or Oregon Health and Science University (OHSU, Oregon, USA). All animal experiments were approved by the institutional Animal Experiments Committee and were executed according to the institutional animal experimentation guidelines and were in compliance with the guidelines of the Institutional, European and Federal USA animal care and usage committees.
Viral titers of virus stocks or infected tissues were determined by plaque assays as previously described . MCMV-IE2-E7 (RAHYNIVTF) and MCMV-IE2-OVA (SIINFEKL) were generated as described . MCMV-IE2-E6/E7 full length fusion, MCMV-IE2-E6/E7 full length replace, MCMV-M79-FKBP-E7 (E7 epitope RAHYNIVTF, IE2 fusion), MCMV-M79-FKBP-gB (gB epitope SSIEFARL, IE2 fusion) were constructed as follows. MCMV BACs were maintained in SW105 E. coli and modified by metabolic galactokinase (galK) selection , essentially as described . In brief, bacteria containing the MCMV backbone were first transformed with a PCR product of galK/kanamycin (kan) and flanking homology to target a specific region in the MCMV BAC. Transformed bacteria were selected for kan resistance, grown and subjected to a second transformation to replace the galK/kan cassette with the final insert. These included annealed oligos used for IE2 peptide fusion or the PCR product for M79-FKBP  and HPV E6/E7 insertions containing the desired modification with the same MCMV flanking homology to insert the galK/kan cassette. Recombinant bacteria were counter-selected on chloramphenicol 2-deoxy-galactose (DOG) minimal media plates with glycerol as the carbon source. MCMV BAC constructs were characterized by restriction digest, PCR screening, and Sanger and NGS sequencing. Virus was reconstituted by either Lipofectamine 3000 (ThermoFisher Scientific) transfection or electroporation (250 V and 950 uF) of NIH 3T3s.
Tissue culture-derived stocks of the MCMV vectors were amplified and titered in NIH 3 T3 cells grown in complete growth media (DMEM, FBS, PSG). FKBP-tagged viruses were grown in complete growth media supplemented with Shield-1 at a final concentration of 1 uM and added every 48 h . Cell free virus was obtained from supernatant of infected cells, clarified at 3.000 rpm for 20 min and virus was pelleted at 24.000 rpm for 1 h through a sorbitol cushion (10% D-sorbitol, 0.05 M Tris pH 7.4, 1 mM MgCl2). Virus pellet was resuspended in PBS. For virus quantification, plaque assays were performed in 24-well plates by infection with appropriate serial virus dilution in 0.2 mL of media and then incubated at 37 °C for 2 h rocking. Following incubation, the infected cells were overlaid with 1 mL complete media supplemented with carboxymethylcellulose. After 5 to 6 days, the cells were fixed in 3.7% formaldehyde in PBS and stained with 0.001% aqueous methylene blue. The plaques were counted by light microscopy. Multi-step virus replication curves were performed in NIH 3 T3 cells at MOI 0.1 in 6 well plates, 3 replicates per virus per time-point. Virus was incubated at 37 °C for 2 h, washed 3 times with PBS and then 2 mL of media was added. Supernatant was harvested at 1, 3, 5, and 7 days post-infection, stored at − 80 °C and titered by plaque assay. FKBP-tagged viruses were grown in complete growth media supplemented with Shield-1 at a final concentration of 1 uM and added every 48 h.
Tumor challenge models and anti-tumor vaccination
The tumor cell line TC-1 (a kind gift from T.C. Wu, John Hopkins University, Baltimore, MD) was generated by retroviral transduction of C57BL/6 lung epithelial cells with the HPV16 E6/E7 and c-H-ras oncogenes  and cultured as previously described . The tumor cell line C3 was developed by transfection of mouse embryonic cells with the HPV16 genome and an activated-ras oncogene and maintained as previously described . The MC38-OVA tumor cell line is generated by a retroviral infection of the MC38 parental cell-line with PMIG/MSCV-IRES-GFP plasmid encoding cytoplasmic bound OVA . Iscove’s Modified Dulbecco’s Media (IMDM) (Lonza, Basel, Switzerland) supplemented with 8% fetal calf serum (FCS) (Greiner), 2 mM L-glutamine (Life Technologies, Carlsbad, CA, Unites States), 50 IU/ml Penicillin (Life Technologies) and 50 μg/ml Streptomycin (Life Technologies) was used to culture tumor cell lines. Cells were cultured in a humidified incubator at 37 °C and 5% CO2. Mycoplasma tests that were frequently performed for all cell lines by PCR were negative.
Treatment schedule of experiments are indicated in the respective figures and legends. Mice were vaccinated with MCMV vectors via the intraperitoneal (IP), intranasal (IN) or subcutaneous (SC) route with the indicated inoculum size. In tumor experiments, mice were inoculated subcutaneously in the flank with 0.25–1 × 105 TC-1 tumor cells, 5 × 105 C3 tumor cells or with 2.5 × 105 MC38-OVA in 200 μl PBS containing 0.2% BSA on day 0. Tumor size was measured two times a week using a caliper. Mice were euthanized when tumor size reached > 1000 mm3 in volume or when mice lost over > 20% of their total body weight (relative to initial body mass).
In vivo antibody usage
CD8 T cell depleting monoclonal antibodies (clone 2.43) were purchased from Bio-X-Cell (West Lebanon, NH, United States) and administered IP twice weekly (200 μg/mouse) for 2–3 weeks. CD8 T cell depletion was started 4 days before tumor challenge. Depletion was checked by staining for CD3 and CD8 marker expression followed by flow cytometric analysis.
Blood collection and processing was performed as described . Cells were re-suspended in staining buffer (PBS + 2% FCS + 0.05% sodium azide) and incubated with various fluorescently labelled antibodies detecting CD8 (clone 53–6.7), CD62L (clone MEL-14), CD44 (clone IM7), KLRG1 (clone 2F1), CD3 (clone 500A2), CD127 (clone A7R34). Antibodies were obtained from eBioscience (San Diego, CA, United States), BD Biosciences (San Jose, CA, United States) and Biolegend (San Diego, CA, United States). For dead cell exclusion, 7-Aminoactinomycin D (Invitrogen, Carlsbad, CA, United States) was used. To measure the MCMV-specific and tumor antigen-specific T cell responses, PE and APC-labelled class I-restricted multimers (tetramers or dextramers) with the peptide epitopes OVA257–264 (SIINFEKL), HPV E749–57 (RAHYNIVTF), MCMV M45985–993 (HGIRNASFI), MCMV M38316–323 (SSPPMFRV) were used. Tetramers were produced as described  and dextramers were obtained from Immudex. Samples were analyzed with a BD LSRII or LSRFortessa flow cytometer, and results were analyzed using FlowJo software (Tree Star, Ashland, OR, United States).
In vivo cytotoxicity assay
Splenocytes of naïve CD45.1 (Ly5.1) mice were isolated and loaded with MHC class I restricted-E749–57 or OVA257–264 peptides for 1 h at 37 °C at the final concentration of 1 μg/ml. After extensive washing, cells which were pulsed with specific peptide or irrelevant peptide were labelled with high and low concentrations of CFSE (Invitrogen), respectively. Next, 5 × 106 peptide pulsed cells were pooled and injected intravenous (IV) via the retro-orbital route into the mice that have been vaccinated 70 days earlier with MCMV-based vaccines. After 24 h, spleens of the recipient mice were isolated, stained for CD45.1, and subjected to flow cytometry. The cytotoxic capacity was calculated relative to naïve mice by using the following formula: [100 – ((percentage of pulsed peptide in infected mice/percentage of unpulsed peptide in infected mice)/(percentage of pulsed peptide in naive mice/percentage of unpulsed peptide in naive mice)] × 100.
Enzyme-linked ImmunoSpot (ELISpot) assay
Splenocytes of individual vaccinated mice were isolated and cultured on ELISpot plates (R&D systems, Minneapolis MN) pre-coated with anti-IFN-γ antibodies. The indicated peptides (E749–57, RAHYNIVTF; or a pool of peptides spanning the E7 sequence, 15-mers overlapping by 11) were added at 1 μg/ml. 36 h later cells were removed and secondary antibodies added. Plates were developed according to the manufactures instructions. Spots were counted using an AID ELISpot reader.
Statistical analyses were performed using GraphPad Prism (La Jolla, CA, Unites States). Survival data were analyzed by Kaplan-Meier and the log-rank (Mantel-Cox) test. Statistical significance was determined by Mann Whitney. P-values of ≤0.05 were considered statistically significant.
Location and size of foreign sequences in CMV-based vaccine vectors impact vaccine-elicited T cell responses and associated tumor protection
Next, we analyzed the impact of the size of the E6/E7 antigens, and therefore generated a recombinant MCMV expressing only a single immunodominant CD8 T cell epitope, i.e. RAHYNIVTF (E749–57), fused to the carboxyl terminus of the MCMV IE2 gene (MCMV-IE2-E7). Clearly, mice immunized with MCMV-IE2-E7 resulted in the highest E7-specific T cell response (~ 2–8%), and vaccination with MCMV-IE2-E7 fully protected mice against otherwise lethal TC-1 tumor challenge (Fig. 1c and d). In conclusion, both the location and size of inserted foreign sequences impact the vaccine-elicited T cell response of MCMV vaccine vectors and this corresponds to protection against tumor outgrowth.
The magnitude of inflationary T cell responses elicited by recombinant MCMV-based vaccine vectors is influenced by the inoculation route and dose and determines vaccine efficacy
Characteristic for inflationary T cells is their effector-memory (EM) like (CD44+CD62Llow, CD127+/−, KLRG1+) appearance . Early after IP and SC immunization, the E7-specific CD8+ T cell population acquired an EM-like phenotypic profile, which remained high throughout the memory phase (Fig. 2c). The M38-specific CD8+ T cells displayed a gradual increase of the EM phenotype to 70–80% of the total Ag-specific T cell population. In contrast, only 40% of the M45-specific CD8+ T cells showed an EM phenotype throughout the memory phase. Upon IN immunization, the formation of the EM phenotype by the E7, M38 and M45-specific CD8+ T cells was much less pronounced (Fig. 2c). Taken together, these data show that immunization with recombinant MCMV vectors via the IP and SC route induces prominent EM-like CD8+ T cell responses, albeit with different kinetics, while IN infection resulted in weak responses at best.
To assess the capacity of CMV-based vaccines to elicit responses to other inserted foreign epitopes, we tested MCMV expressing the H-2Kb-restricted OVA257–264 (SIINFEKL) epitope from ovalbumin (OVA). Immunization with MCMV-IE2-OVA induced OVA-specific CD8+ T cell responses against OVA257–264 that were slightly higher than the response against E7 after MCMV-IE2-E7 immunization. The responses against the epitopes in M38 and M45 were similar (Additional file 1: Figure S1A). Moreover, vaccination with MCMV-IE2-OVA induced complete protection against OVA-expressing MC38 tumor cells (Additional file 1: Figure S1B).
Immunity to re-infection can hamper the formation of vaccine-induced CD8+ T cell responses
To assess how various levels of pre-existing MCMV immunity influence the tumor protection, mice with low and high pre-existing immunity were challenged with TC-1 tumor cells (Fig. 6b and c). Mice with a high level of pre-existing immunity (infected previously with a high dose MCMV-IE2-OVA via the IP route) and vaccinated IP, SC or IN with MCMV-IE2-E7 were not protected (Fig. 6b and c, Group 4, 5 and 6). This correlated with the elicited E7-specific responses in the blood that were < 0.3%, except for one mouse in group 5 (SC vaccinated) which cleared the tumor and correspondingly had an E7-specific CD8+ T cell responses > 0.3% (Fig. 6a and d). Moreover, infection with a 1000 fold lower inoculum dosage of MCMV-IE2-OVA via the IP route followed by IP vaccination with MCMV-IE2-E7 resulted in partial protection (Fig. 6b and c, Group 7). Remarkably, the unprotected mice in this group had E7-specific CD8+ T cell responses < 0.3% while all protected mice had responses > 0.3% (Fig. 6d). Moreover, in mice infected with MCMV-IE2-OVA via the IN route and then vaccinated with MCMV-IE2-E7 via the IP and SC route, none of the tumors grew out and the mice remained tumor-free (Fig. 6b and c, Group 2 and 3). Importantly, these mice had E7-specific CD8+ T cell responses in the blood > 0.3% (Fig. 6a and d). Taken together, these data indicate that the level of pre-existing immunity can set the protection threshold of vaccine-induced CD8+ T cell responses by CMV-based vaccine vectors: a strong T cell response against the vaccine vector elicited during primary infection inversely correlates with the ability of an MCMV-vectored vaccine to elicit protective immunity upon super-infection.
Single-cycle replication is sufficient for the anti-tumor efficacy of MCMV based vaccine vectors
To investigate the efficacy of MCMV-based vaccine vectors in therapeutic settings, we challenged naïve mice with TC-1 tumor cells followed by vaccination when tumors were palpable. Tumor-bearing mice vaccinated with MCMV-IE2-E7 and with MCMV-M79-FKBP-E7 via the IP and SC route resulted in substantial suppression of tumor outgrowth (Fig. 7g and Additional file 3: Figure S3B). Together these data indicate that a single-cycle MCMV-based vector could offer a safe vaccine platform to induce effective anti-tumor CD8+ T cell responses in prophylactic and therapeutic settings.
Here we interrogated whether vaccination thresholds based on the level of tumor-specific T cells elicited by CMV-based vaccines can be sharply defined in order to provide correlates of protection. In addition, we examined the critical factors impacting on the protection threshold and hence the efficacy of CMV-based vaccines against cancer. Fundamentally, we found that CMV-based vaccine vectors have the capacity to provide long-lasting tumor-specific T cell responses that protect against tumors, provided that such responses reach a defined threshold.
CMV-based vectors are thus able to generate defined thresholds of circulating vaccine-specific CD8 T cells that provide long-lasting tumor protection. The factors that determine this threshold such as virus dose, route of vaccination and pre-existing immunity have to be extensively studied to consider the development of effective CMV-based vaccines in cancer patients. CMVs are large viruses (> 230 Kb) encoding more than 170 proteins. Although large viral vaccine vectors eliciting strong T cell responses could possibly lead to competition for antigen-presentation and “space”, which may limit additional T cell responses, this seems not to hamper vaccine-specific T cell responses elicited by CMV. Both in mice and monkeys, CMVs have shown to be very potent inducers of T cell responses to antigens in SIV, Mycobacterium tuberculosis, Ebola [14, 15, 16, 17, 18] and several cancers including melanoma, prostate cancer and HPV+ cancer (unpublished data Klaus Früh). With respect to space limitation for effector-memory T cells. There is evidence in mice and human that superinfections are able to add more T cells to the memory pool [36, 37]. Although, the percentage of a given T cell population can decrease when more memory T cells are added to the memory pool the absolute numbers of a given T cell population generally does not reduce.
Defined thresholds for protection based on disease-specific T cells have been scarcely reported. Schmidt et al. reported that protection against malaria required a large threshold in memory CD8 T cell frequencies, i.e. > 1% specific T cells of the total CD8+ T cell population in blood . Here we found that a threshold of > 0.3% specific blood CD8+ T cells links to full tumor protection. The sharp threshold we observed suggest that the elicited tumor-specific T cells have a controlled capacity to kill target cells, which is in line with studies showing that the in vivo killing capacity of CD8+ T cells is marked yet restricted . This demarcated threshold is clearly reached upon vaccination with high dose inoculums of MCMV vectors delivered via the IP and SC route, and protects against the development of subcutaneous tumors. On the other hand, immunization via the IN route, considered as a natural route of infection , resulted in minor vaccine-specific responses and hence lower protection. However, IN immunization was superior in protection against respiratory pathogens compared to IP immunization due to enhanced induction of tissue-resident memory (TRM) T cells . It is thus conceivable that lung tumors are better controlled following vaccination via the IN route. In line with this are the observations that upon SC immunization some mice (10–30%) are protected despite that the tumor-specific CD8+ T cell response in the blood is below the threshold. In these mice, the SC immunization may have led to induction of skin TRM cells, known to be able to provide tumor protection .
Besides the quantity it is expected that the phenotype of the elicited cells is of influence for the effectivity. Inflating or indefinitely maintained CMV-elicited T cell populations are characterized by their progressive EM-like phenotype [43, 44] and such responses seem to be qualitatively different from CM T cells with respect to their immediate effector functions and tissue homing properties . These features are important for protection against viruses at their sites of entry or reactivation, and may as well be crucial for clearance of tumors arising e.g. from epithelial or endothelial cells, or metastasis. Here and also reported elsewhere  a correlation between the magnitude and phenotype was observed. The combination of phenotype with magnitude provides a better predictor for protective thresholds than either parameter alone.
We found that high levels of pre-existing immunity elicited by SC or IP immunization hamper the development of vaccine-specific T cell responses due to anti-vector immunity thereby reducing the efficacy of MCMV-based vaccine vectors. In contrast, induction of pre-existing immunity by the natural IN route enables sufficient formation of vaccine-specific T cells upon re-inoculation leading to tumor protection. In support of the conclusion that CMVs can overcome natural immunity is also the observation that strains of HCMV have been reported to frequently re-infect seropositive individuals [47, 48]. Moreover, naturally infected seropositive rhesus macaques can be readily re-infected with rhesus CMV (RhCMV) even when given SC at very low dose . Also, RhCMV/SIV vector-immunized monkeys can be repeatedly re-infected via the SC route . In this animal model, the ability to re-infect has been shown to be in part due to the effective inhibition of MHC-I antigen presentation . It may be possible to engineer recombinant HCMV vectors that are able to induce strong and protective immune responses despite pre-existing immunity. For rhesus macaques it was already shown that RhCMV vectors containing SIV antigens provide strong vector-elicited T cell immunity and protection against highly virulent SIV challenge in CMV positive animals . Interestingly, the specific vaccine vectors used in these challenge experiments were highly unusual in their T cell targeting phenotype since they elicited CD8+ T cells recognizing epitopes presented by MHC class II and MHC-E molecules . Unconventional T cell priming was in part due to conserved MHC class I evasion mechanisms and in part the result of spontaneous genetic changes that occurred in the vectors due to passaging in fibroblasts. However, fibroblast-adapted HCMV-based vaccines did neither elicit HCMV-typical strong effector memory T cell responses nor were the responses unconventional suggesting that unconventional T cell priming is the result of specific mutations that occurred in fibroblasts-adapted RhCMV, but not HCMV . It remains thus to be determined whether HCMV vectors can be engineered both to overcome strong pre-existing immunity and to elicit the desired CD8 T cell response, be it conventional or unconventional, required for protection against specific infectious diseases or cancer. Alternatively, MCMV-based vectors might be used in the clinic as human cells can be abortively infected, still leading to expression and presentation of virally vectored genes [53, 54].
Synthetic vaccines and other viral vectors (than CMV-based such as recombinant vaccinia virus) eliciting T cell responses to the HPV-16 tumor antigens E6/E7 have also been extensively studied [31, 55, 56, 57, 58, 59, 60], and some of these vaccines have also shown effectiveness in the clinic [61, 62, 63]. Although long-lasting responses with some of these vaccines were accomplished (especially after boosting), the percentage of circulating HPV-specific CD8+ T cell responses seemed to be lesser as compared to the responses elicited by MCMV-IE2-E7 as reported here. Whether CMV-based vaccines are effective in patients still needs to be determined, and to accomplish this additional testing is required. A single high-dose vaccination may already be sufficient given the potential induction of large vaccine-specific CD8+ T cell responses. Booster regimens with the same CMV-based vectors in therapeutic settings may not work because of high-levels of pre-existing immunity and/or acquired tumor cell resistance after the initial immunization . Yet given their promising results in experimental models an endeavour to test CMV-vectors in the clinic is worth pursuing.
In conclusion, we show that protective thresholds upon immunization with MCMV vectors can be sharply defined via determination of tumor-specific CD8 T cells in blood, and that the inoculum dosage and route of infection are crucial elements determining the magnitude of these cells. In addition, our study shows the importance of determining the level of pre-existing immunity for CMV-based vaccines and suggests including stratification based on the magnitude of CMV-specific T cell responses in pre-vaccinated individuals. The route and dose of immunization may then even be adjusted to improve the vaccine efficacy. Further studies will be needed with the anticipation to improve the efficacy of CMV-based vaccines.
The authors acknowledge Suzanne Welten and Anke Redeker for advice and practical help. The authors would like to thank Jan Wouter Drijfhout and Kees Franken for constructing tetramers.
This work was supported by a grant from Leiden University Medical Center (LUMC; E. Beyranvand Nejad), and a Gisela Thier grant from LUMC (R. Arens).
Availability of data and materials
All data generated or analyzed during this study are included in this published article [and its Additional files].
EB, RB, KF, SB and RA contributed to the study concepts and study design. Data acquisition was performed by EB, RB, EP, CM, JO. All the authors contributed to the quality control data, analysis and interpretation of data. The manuscript preparation was performed by EB and RA and edited by all authors. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All animal experiments were approved by the institutional Animal Experiments Committee and were executed according to the institutional animal experimentation guidelines and were in compliance with the guidelines of the Institutional, European and Federal USA animal care and usage committees.
Consent for publication
We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.
We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 1.Redeker A, Arens R. Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol. 2016;7:345.Google Scholar
- 3.van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016;16(4):219-33.Google Scholar
- 11.Trgovcich J, Kincaid M, Thomas A, Griessl M, Zimmerman P, Dwivedi V, et al. Cytomegalovirus Reinfections Stimulate CD8 T-Memory Inflation. PLoS One. 2016;11(11):e0167097.Google Scholar
- 13.Borst EM, Benkartek C, Messerle M. Use of bacterial artificial chromosomes in generating targeted mutations in human and mouse cytomegaloviruses. Curr Protoc Immunol. 2007; Chapter 10:Unit.Google Scholar
- 36.van Leeuwen EM, Koning JJ, Remmerswaal EB, van BD, van Lier RA, ten Berge IJ. Differential usage of cellular niches by cytomegalovirus versus EBV- and influenza virus-specific CD8+ T cells. J Immunol 2006;177(8):4998–5005.Google Scholar
- 40.Oduro JD, Redeker A, Lemmermann NA, Ebermann L, Marandu TF, Dekhtiarenko I, et al. Murine cytomegalovirus infection via the intranasal route offers a robust model of immunity upon mucosal CMV infection. J Gen Virol. 2016;97(1):185-95.Google Scholar
- 44.Pardieck IN, Beyrend G, Redeker A, Arens R. Cytomegalovirus infection and progressive differentiation of effector-memory T cells. F1000Res. 2018;7:1554.Google Scholar
- 52.Murray SE, Nesterenko PA, Vanarsdall AL, Munks MW, Smart SM, Veziroglu EM, et al. Fibroblast-adapted human CMV vaccines elicit predominantly conventional CD8 T cell responses in humans. J Exp Med. 2017;31(20161988):20161988.Google Scholar
- 63.van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof NM. Berends-van der Meer DM, et al. vaccination against Oncoproteins of HPV16 for noninvasive vulvar/vaginal lesions: lesion clearance is related to the strength of the T-cell response. Clin Cancer Res. 2016;22(10):2342–50.CrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.